for its ActiCells™ GMP Human Induced Pluripotent Stem Cell (hiPSC) line. This milestone underscores the company’s commitment to empowering scientists to accelerate their cell therapy ...

In a first-of-its-kind human trial, researchers transplanted iPS-cell-derived dopaminergic progenitors into patients with ...

In a small study, researchers transplanted stem cells into the brains of 12 Parkinson’s patients, stopping progression and ...

In one trial, researchers injected cells from a human embryonic-stem-cell line into the midbrains of 12 middle-aged people with Parkinson’s. Once a line is established, these lab-grown cells can ...

A team of CiRA researchers has uncovered the crucial role of EIF3D—a protein translational regulator—in primed pluripotency.

2 describe the outcome of a phase I clinical trial in which 12 people in the United States and Canada were treated with dopaminergic progenitor cells derived from a human embryonic stem-cell line.

A stem cell–based therapy initially developed at Memorial Sloan Kettering Cancer Center (MSK) may lead to a new treatment for advanced Parkinson's disease, according to results from a phase 1 clinical ...

Parkinson’s disease primarily affects dopamine neurons in the substantia nigra, a region of the brain crucial for movement and emotional regulation. As these neurons die, the brain’s dopamine levels ...

Two independent clinical trials demonstrate the safety of stem cell therapies for Parkinson’s disease. The papers, published in Nature, investigate the use of cells derived from human ...

Applied StemCell solidifies their commitment to cell therapy development with a DMF submitted to the US FDA for the ActiCells™ GMP hiPSC line.